| Autor: |
Xie S; College of Chemistry, Fuzhou University, Fuzhou, China., Cao S; College of Chemistry, Fuzhou University, Fuzhou, China., Wu J; College of Chemistry, Fuzhou University, Fuzhou, China., Xie Z; College of Chemistry, Fuzhou University, Fuzhou, China., Liu YT; Xiamen ITG-SUIS High School, Xiamen, China., Fu W; College of Chemistry, Fuzhou University, Fuzhou, China., Zhao Q; College of Pharmacy, Chongqing Medical University, Chongqing, China., Liu L; College of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, China., Yang L; Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China., Li J; College of Chemistry, Fuzhou University, Fuzhou, China. |
| Abstrakt: |
The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide has led to over 600 million cases of coronavirus disease 2019 (COVID-19). Identifying effective molecules that can counteract the virus is imperative. SARS-CoV-2 macrodomain 1 (Mac1) represents a promising antiviral drug target. In this study, we predicted potential inhibitors of SARS-CoV-2 Mac1 from natural products using in silico -based screening. Based on the high-resolution crystal structure of Mac1 bound to its endogenous ligand ADP-ribose (ADPr), we first performed a docking-based virtual screening of Mac1 inhibitors against a natural product library and obtained five representative compounds (MC1-MC5) by clustering analysis. All five compounds were stably bound to Mac1 during 500 ns long molecular dynamics simulations. The binding free energy of these compounds to Mac1 was calculated using molecular mechanics generalized Born surface area and further refined with localized volume-based metadynamics. The results demonstrated that both MC1 (-9.8 ± 0.3 kcal/mol) and MC5 (-9.6 ± 0.3 kcal/mol) displayed more favorable affinities to Mac1 with respect to ADPr (-8.9 ± 0.3 kcal/mol), highlighting their potential as potent SARS-CoV-2 Mac1 inhibitors. Overall, this study provides potential SARS-CoV-2 Mac1 inhibitors, which may pave the way for developing effective therapeutics for COVID-19.Communicated by Ramaswamy H. Sarma. |
